PDCD1 and neoplasm: Finally, targeting the tumor microenvironment (TME) with immune checkpoint inhibitors that block the programmed cell death-1 (PD-1) and cytotoxic T-lymphocyte associated protein 4 (CTLA4) pathways is becoming routine and can complement the above approaches for precision medicine (part 6 in Figure 2).